Trial Profile
In patients with chronic epiphora due to partial, complete, or functional nasolacrimal duct obstruction, is lacrimal gland botulinum toxin injection more effective at reducing subjective symptoms as compared to placebo?
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Jul 2016
Price :
$35
*
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Euphoria
- Focus Therapeutic Use
- 01 Jul 2016 New trial record